{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:24:07Z","timestamp":1783002247093,"version":"3.54.5"},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["BIOT"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Human MxA gene is related to the class of interferon (IFN)-stimulated genes (ISGs) that plays a role in antiviral resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Implementation of standard curves obtained from designing a procedure for data processing in relative qPCR between MxA expression and interferon\u2019s antiviral activity (IU\/ml). These standard curves can be used to detect the antiviral activity of any new compound rapidly and safely.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>To detect the optimum incubation time for maximum MxA gene expression in human peripheral blood mononuclear cells (PBMC), the isolated human PBMCs (1x106 cells) were incubated with a concentration of 1000 IU\/ml of each IFN at different time intervals; 2 h, 4 h, 6 h, and 24 h post-treatment. A standard curve was performed for each IFN (\u03b1, \u03b2, and \u03b3) at different concentrations (250, 500, 750, 1000, 1500, and 2000 IU\/ml).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>As observed at 4 h incubation time of 1000 IU\/ml concentration, IFN-\u03b3 provided a higher expression of MxA compared to IFN-\u03b1 and IFN-\u03b2. Correlation analyses between IFN-\u03b1 and IFN-\u03b2, IFN-\u03b2 and IFN-\u03b3 were non-significant. However, there was a significant correlation between IFN-\u03b1 and IFN-\u03b3 (p&lt;0.01). Receiver operator characteristic (ROC) analysis revealed that cut-off values of IFN- \u03b3, IFN-\u03b2, and IFN-\u03b1 were 58.14 &gt; 7.31 and &gt; 3.33, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The relative expression of MxA is a biomarker for IFN-\u03b1, \u03b2, and \u03b3, especially IFN-\u03b1. It has compiled and validated a standard curve-based protocol for PCR data processing. It shows that the standard curve is an easy alternative tool to assess antiviral activity. We revised all patents relating to the antiviral assays of the used interferons.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1872208314666201112105053","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:31:53Z","timestamp":1605241913000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Novel Cell-based In vitro Assay for Antiviral Activity of Interferons \u03b1, \u03b2, and \u03b3 by qPCR of MxA Gene Expression"],"prefix":"10.2174","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-450X","authenticated-orcid":true,"given":"Mohamed A.","family":"Saber","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza,Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1125-245X","authenticated-orcid":true,"given":"Hend","family":"Okasha","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza,Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-1239","authenticated-orcid":true,"given":"Fatma","family":"Khorshed","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza,Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-0448","authenticated-orcid":true,"given":"Safia","family":"Samir","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza,Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.4110\/in.2018.18.e33","volume":"18","author":"Kang S.","year":"2018","unstructured":"Kang S.; Brown H.M.; Hwang S.; Direct antiviral mechanisms of interferon-gamma. Immune Netw 2018,18(5),e33","journal-title":"Immune Netw"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.31838\/ijpr\/2020.12.02.0008","volume":"12","author":"Okasha H.","year":"2020","unstructured":"Okasha H.; Interferon and p53 tumor suppressor marker in hepatocellular carcinoma. Int J Pharm Res 2020,12(2),11-14","journal-title":"Int J Pharm Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/1872208311666170301103722","volume":"11","author":"Venkataraman S.","year":"2017","unstructured":"Venkataraman S.; Ahmad T.; AbouHaidar M.G.; Hefferon K.L.; Virus-based rna silencing agents and virus-derived expression vectors as gene therapy vehicles. Recent Pat Biotechnol 2017,11(2),141-151","journal-title":"Recent Pat Biotechnol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fimmu.2017.00029","volume":"8","author":"Majoros A.","year":"2017","unstructured":"Majoros A.; Platanitis E.; Kernbauer-H&#xF6;lzl E.; Rosebrock F.; M&#xFC;ller M.; Decker T.; Canonical and non-canonical aspects of JAK-STAT signaling: Lessons from interferons for cytokine responses. Front Immunol 2017,8(29),29","journal-title":"Front Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.31838\/ijpr\/2020.12.02.0008","volume":"12","author":"Okasha H.","year":"2020","unstructured":"Okasha H.; Interferon and p53 tumor suppressor marker in hepatocellular carcinoma,&#x201D; Int J Pharm Res 2020,12(2),11","journal-title":"Int J Pharm Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00335-018-9755-6","volume":"29","author":"Green R.","year":"2018","unstructured":"Green R.; Ireton R.C.; Gale M.; Interferon-stimulated genes: new platforms and computational approaches. Mamm Genome 2018,29(7-8),593-602","journal-title":"Mamm Genome"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"Sarasin-Filipowicz M.","year":"2008","unstructured":"Sarasin-Filipowicz M.; Oakeley E.J.; Duong F.H.; Christen V.; Terracciano L.; Filipowicz W.; Heim M.H.; Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008,105(19),7034-7039","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri2314","volume":"8","author":"Sadler A. J.","year":"2008","unstructured":"Sadler A. J.; Williams B. R. G.; \"Interferon-inducible antiviral effectors,&#x201D; Nat Rev Immunol 2008,8(7),559-568","journal-title":"Nat Rev Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","volume":"4","author":"Mesev E. V.","year":"2019","unstructured":"Mesev E. V.; LeDesma R. A.; Ploss A.; &#x201C;Decoding type I and III interferon signalling during viral infection,&#x201D; Nat Microbiol 2019,4(6),914-924","journal-title":"Nat Microbiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fimmu.2019.00325","volume":"10","author":"Jefferies C.A.","year":"2019","unstructured":"Jefferies C.A.; Regulating IRFs in IFN driven disease. Front Immunol 2019,10(325),325","journal-title":"Front Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-0404.2007.00968.x","volume":"118","author":"Vallittu A.M.","year":"2008","unstructured":"Vallittu A.M.; Er&#xE4;linna J.P.; Ilonen J.; Salmi A.A.; Waris M.; MxA protein assay for optimal monitoring of IFN-&#x3B2; bioactivity in the treatment of MS patients. Acta Neurol Scand 2008,118(1),12-17","journal-title":"Acta Neurol Scand"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e1007420","DOI":"10.1371\/journal.ppat.1007420","volume":"14","author":"Pervolaraki K.","year":"2018","unstructured":"Pervolaraki K.; Rastgou Talemi S.; Albrecht D.; Bormann F.; Bamford C.; Mendoza J.L.; Garcia K.C.; McLauchlan J.; H&#xF6;fer T.; Stanifer M.L.; Boulant S.; Bormann F, Bamford C, Mendoza JL, et al. Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance. PLoS Pathog 2018,14(11),e1007420","journal-title":"PLoS Pathog"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1365-2893.2009.01241.x","volume":"17","author":"Shaker O.","year":"2010","unstructured":"Shaker O.; Ahmed A.; Doss W.; Abdel-Hamid M.; MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. J Viral Hepat 2010,17(11),794-799","journal-title":"J Viral Hepat"},{"key":"ref=14","first-page":"84","volume":"4","author":"Saber M.A.","year":"2020","unstructured":"Saber M.A.; Samir El-Naggar S.; Hassanein M.H.; Barakat A.B.; &#x201C;Role of Mxa and neutralizing antibodies in early response to interferon treatment in Hepatitis C Egyptian patients,&#x201D; Eur J Biomed Pharm Sci 2020,4(2),84-94","journal-title":"Eur J Biomed Pharm Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/0042-6822(59)90135-7","volume":"9","author":"Ho M.","year":"1959","unstructured":"Ho M.; Enders J.F.; Further studies on an inhibitor of viral activity appearing in infected cell cultures and its role in chronic viral infections. Virology 1959,9(3),446-477","journal-title":"Virology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/7651_2014_99","volume":"1304","author":"Riedhammer C.","year":"2016","unstructured":"Riedhammer C.; Halbritter D.; Weissert R.; Peripheral blood mononuclear cells: Isolation, freezing, thawing, and culture. Methods Mol Biol 2016,1304,53-61","journal-title":"Methods Mol Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e323.","DOI":"10.21769\/BioProtoc.322","volume":"3","author":"Panda S.","year":"2013","unstructured":"Panda S.; Ravindran B.; In vitro Culture of Human PBMCs. Bio Protoc 2013,3(3),e323.","journal-title":"Bio Protoc"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1128\/JVI.00546-06","volume":"81","author":"Holzinger D.","year":"2007","unstructured":"Holzinger D.; Jorns C.; Stertz S.; Boisson-Dupuis S.; Thimme R.; Weidmann M.; Casanova J.L.; Haller O.; Kochs G.; Boisson-Dupuis S, Thimme R, Weidmann M, et al. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 2007,81(14),7776-7785","journal-title":"J Virol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1086\/314859","volume":"180","author":"Fern&#xE1;ndez M.","year":"1999","unstructured":"Fern&#xE1;ndez M.; Quiroga J.A.; Mart&#xED;n J.; Herrero M.; Pardo M.; Horisberger M.A.; Carre&#xF1;o V.; Herrero M, Pardo M, Horisberger MA, et al. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 1999,180(2),262-267","journal-title":"J Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/B978-0-12-800969-7.00005-0","author":"Delong R.K.","year":"2015","unstructured":"Delong R.K.; Zhou Q.; Introductory experiments on biomolecules and their Interactions 2015,45-57","journal-title":"Introductory experiments on biomolecules and their Interactions"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.26452\/ijrps.v10i4.1574","volume":"10","author":"Okasha H.","year":"2019","unstructured":"Okasha H.; Hassan M.; Aboushousha T.; Samir S.; Effect of Interferon-Beta (IFN-&#x3B2;) on tumor suppressor and apoptotic markers in hepatocellular carcinoma cell line. Int J Res Pharm Sci 2019,10(4),2936-2943","journal-title":"Int J Res Pharm Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"100571","DOI":"10.1016\/j.genrep.2019.100571","volume":"18","author":"Okasha H.","year":"2020","unstructured":"Okasha H.; Samir S.; Synthesis and molecular cloning of antimicrobial peptide chromogranin A N-46 gene using conventional PCR. Gene Rep 2020,18,100571","journal-title":"Gene Rep"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"Livak K.J.","year":"2001","unstructured":"Livak K.J.; Schmittgen T.D.; Analysis of relative gene expression data using real-time quantitative PCR and the 2(-\u0394 \u0394 C(T)) method. Methods 2001,25(4),402-408","journal-title":"Methods"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jim.2006.12.012","volume":"321","author":"Bertolotto A.","year":"2007","unstructured":"Bertolotto A.; Sala A.; Caldano M.; Capobianco M.; Malucchi S.; Marnetto F.; Gilli F.; , Capobianco M, Malucchi S, Marnetto F, et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 2007,321(1-2),19-31","journal-title":"J Immunol Methods"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/1872208313666190924162831","volume":"14","author":"Mozafari M.","year":"2020","unstructured":"Mozafari M.; Tariverdian T.; Beynaghi A.; Trends in biotechnology at the turn of the millennium. Recent Pat Biotechnol 2020,14(1),78-82","journal-title":"Recent Pat Biotechnol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2217\/fvl.09.1","volume":"4","author":"Saxena S.K.","year":"2009","unstructured":"Saxena S.K.; Mishra N.; Saxena R.; Advances in antiviral drug discovery and development: part II: Advancements in antiviral drug development. Future Virol 2009,4(3),209-215","journal-title":"Future Virol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/18722083113079990006","volume":"7","author":"Bernardes J.S.","year":"2013","unstructured":"Bernardes J.S.; Pedreira C.E.; A review of protein function prediction under machine learning perspective. Recent Pat Biotechnol 2013,7(2),122-141","journal-title":"Recent Pat Biotechnol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.tim.2014.12.003","volume":"23","author":"Haller O.","year":"2015","unstructured":"Haller O.; Staeheli P.; Schwemmle M.; Kochs G.; Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 2015,23(3),154-163","journal-title":"Trends Microbiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/j.ijid.2011.05.002","volume":"15","author":"Gao X.F.","year":"2011","unstructured":"Gao X.F.; Yang Z.W.; Li J.; Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis 2011,15(9),e594-e600","journal-title":"Int J Infect Dis"},{"key":"ref=30","first-page":"153","volume":"22","author":"Lalle E.","year":"2008","unstructured":"Lalle E.; Calcaterra S.; Horejsh D.; Abbate I.; D\u2019Offizi G.; Abdeddaim A.; Vlassi C.; Antonucci G.; Capobianchi M.R.; Abbate I, D\u2019Offizi G, Abdeddaim A, et al. Ability of peripheral blood mononuclear cells to activate interferon response in vitro is predictive of virological response in HCV patients. J Biol Regul Homeost Agents 2008,22(3),153-160","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=31","first-page":"23","author":"Grossberg S.E.","year":"1984","unstructured":"Grossberg S.E.; Jameson P.M.; Sedmak J.J.; 1984,23-43"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/1872208313666191114151344","volume":"14","author":"Abd El-Baky H.H.","year":"2020","unstructured":"Abd El-Baky H.H.; El-Baroty G.S.; Spirulina maxima L-asparaginase: immobilization, antiviral and antiproliferation activities. Recent Pat Biotechnol 2020,14(2),154-163","journal-title":"Recent Pat Biotechnol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1089\/jir.1996.16.637","volume":"16","author":"Mire-Sluis A.R.","year":"1996","unstructured":"Mire-Sluis A.R.; Gaines Das R.; Zoon K.; Padilla A.; Thorpe R.; Meager A.; The biological properties, assay, and standardization of interferon-alpha: a need for a WHO collaborative study. J Interferon Cytokine Res 1996,16(8),637-643","journal-title":"J Interferon Cytokine Res"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.4049\/jimmunol.150.5.1715","volume":"150","author":"Ronni T.","year":"1993","unstructured":"Ronni T.; Mel&#xE9;n K.; Malygin A.; Julkunen I.; &#x201C;Control of IFN-inducible MxA gene expression in human cells.,&#x201D; J Immunol 1993,150(5),1715-26 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7679692","journal-title":"J Immunol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.4049\/jimmunol.154.6.2764","volume":"154","author":"Ronni T.","year":"1995","unstructured":"Ronni T.; Sareneva T.; Pirhonen J.; Julkunen I.; Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol 1995,154(6),2764-2774","journal-title":"J Immunol"},{"key":"ref=36","first-page":"170","volume":"13","author":"Ra&#xED;ssa C.D.","year":"2019","unstructured":"Ra&#xED;ssa C.D.; Recent Patents Applications in Red Biotechnology: a mini-review. Recent Pat Biotechnol 2019,13(170),170-186"},{"key":"ref=37","author":"Goldsmith M.A.","year":"2001","unstructured":"Goldsmith M.A.; You Y.; Cell fusion assays for the identification of antiviral compounds, and systems and kits for practicing the same. US Patent 6,451,598., 2001"},{"key":"ref=38","author":"Benjamin B.J.","year":"2004","unstructured":"Benjamin B.J.; Dyall J, Jockel-Balsarotti J, O'Guin A, Olivo P, Roth R, et al. Method of discovery and development of broad-spectrum antiviral drugs. US Patent 10\/766,226, 2004"}],"container-title":["Recent Patents on Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187902\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T07:13:28Z","timestamp":1697094808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187902\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872208314666201112105053","relation":{},"ISSN":["1872-2083"],"issn-type":[{"value":"1872-2083","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}